Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO

<p>Abstract</p> <p>Background</p> <p>Autologous mobilised peripheral blood stem cell (PBSC) transplantation is now a standard approach in the treatment of haematological diseases to reconstitute haematopoiesis following myeloablative chemotherapy. However, there remains...

Full description

Bibliographic Details
Main Authors: Turner Marc L, Davies John, Roddie Huw, Barclay G Robin, Tura Olga
Format: Article
Language:English
Published: BMC 2007-10-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/5/1/53
id doaj-384dbc9ba0a04660be9ac5aff2ed494a
record_format Article
spelling doaj-384dbc9ba0a04660be9ac5aff2ed494a2020-11-25T00:29:21ZengBMCJournal of Translational Medicine1479-58762007-10-01515310.1186/1479-5876-5-53Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPOTurner Marc LDavies JohnRoddie HuwBarclay G RobinTura Olga<p>Abstract</p> <p>Background</p> <p>Autologous mobilised peripheral blood stem cell (PBSC) transplantation is now a standard approach in the treatment of haematological diseases to reconstitute haematopoiesis following myeloablative chemotherapy. However, there remains a period of severe neutropenia and thrombocytopenia before haematopoietic reconstitution is achieved. <it>Ex vivo </it>expanded PBSC have been employed as an adjunct to unmanipulated HSC transplantation, but have tended to be produced using complex cytokine mixtures aimed at multilineage (neutrophil and megakaryocyte) progenitor expansion. These have been reported to reduce or abrogate neutropenia but have little major effect on thrombocytopenia. Selective megakaryocyte expansion has been to date ineffective in reducing thrombocytopenia. This study was implemented to evaluate neutrophil specific rather than multilineage <it>ex vivo </it>expansion of PBSC for specifically focusing on reduction or abrogation of neutropenia.</p> <p>Methods</p> <p>CD34<sup>+ </sup>cells (PBSC) were enriched from peripheral blood mononuclear cells following G-CSF-mobilisation and cultured with different permutations of cytokines to determine optimal cytokine combinations and doses for expansion and functional differentiation and maturation of neutrophils and their progenitors. Results were assessed by cell number, morphology, phenotype and function.</p> <p>Results</p> <p>A simple cytokine combination, SCF + Flt3-L + G-CSF, synergised to optimally expand and mature neutrophil progenitors assessed by cell number, phenotype, morphology and function (superoxide respiratory burst measured by chemiluminescence). G-CSF appears mandatory for functional maturation. Addition of other commonly employed cytokines, IL-3 and IL-6, had no demonstrable additive effect on numbers or function compared to this optimal combination. Addition of TPO, commonly included in multilineage progenitor expansion for development of megakaryocytes, reduced the maturation of neutrophil progenitors as assessed by number, morphology and function (respiratory burst activity).</p> <p>Conclusion</p> <p>Given that platelet transfusion support is available for autologous PBSC transplantation but granulocyte transfusion is generally lacking, and that multilineage expanded PBSC do not reduce thrombocytopenia, we suggest that instead of multilineage expansion selective neutrophil expansion based on this relatively simple cytokine combination might be prioritized for development for clinical use as an adjunct to unmanipulated PBSC transplantation to reduce or abrogate post-transplant neutropenia.</p> http://www.translational-medicine.com/content/5/1/53
collection DOAJ
language English
format Article
sources DOAJ
author Turner Marc L
Davies John
Roddie Huw
Barclay G Robin
Tura Olga
spellingShingle Turner Marc L
Davies John
Roddie Huw
Barclay G Robin
Tura Olga
Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
Journal of Translational Medicine
author_facet Turner Marc L
Davies John
Roddie Huw
Barclay G Robin
Tura Olga
author_sort Turner Marc L
title Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
title_short Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
title_full Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
title_fullStr Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
title_full_unstemmed Optimal <it>ex vivo </it>expansion of neutrophils from PBSC CD34<sup>+ </sup>cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
title_sort optimal <it>ex vivo </it>expansion of neutrophils from pbsc cd34<sup>+ </sup>cells by a combination of scf, flt3-l and g-csf and its inhibition by further addition of tpo
publisher BMC
series Journal of Translational Medicine
issn 1479-5876
publishDate 2007-10-01
description <p>Abstract</p> <p>Background</p> <p>Autologous mobilised peripheral blood stem cell (PBSC) transplantation is now a standard approach in the treatment of haematological diseases to reconstitute haematopoiesis following myeloablative chemotherapy. However, there remains a period of severe neutropenia and thrombocytopenia before haematopoietic reconstitution is achieved. <it>Ex vivo </it>expanded PBSC have been employed as an adjunct to unmanipulated HSC transplantation, but have tended to be produced using complex cytokine mixtures aimed at multilineage (neutrophil and megakaryocyte) progenitor expansion. These have been reported to reduce or abrogate neutropenia but have little major effect on thrombocytopenia. Selective megakaryocyte expansion has been to date ineffective in reducing thrombocytopenia. This study was implemented to evaluate neutrophil specific rather than multilineage <it>ex vivo </it>expansion of PBSC for specifically focusing on reduction or abrogation of neutropenia.</p> <p>Methods</p> <p>CD34<sup>+ </sup>cells (PBSC) were enriched from peripheral blood mononuclear cells following G-CSF-mobilisation and cultured with different permutations of cytokines to determine optimal cytokine combinations and doses for expansion and functional differentiation and maturation of neutrophils and their progenitors. Results were assessed by cell number, morphology, phenotype and function.</p> <p>Results</p> <p>A simple cytokine combination, SCF + Flt3-L + G-CSF, synergised to optimally expand and mature neutrophil progenitors assessed by cell number, phenotype, morphology and function (superoxide respiratory burst measured by chemiluminescence). G-CSF appears mandatory for functional maturation. Addition of other commonly employed cytokines, IL-3 and IL-6, had no demonstrable additive effect on numbers or function compared to this optimal combination. Addition of TPO, commonly included in multilineage progenitor expansion for development of megakaryocytes, reduced the maturation of neutrophil progenitors as assessed by number, morphology and function (respiratory burst activity).</p> <p>Conclusion</p> <p>Given that platelet transfusion support is available for autologous PBSC transplantation but granulocyte transfusion is generally lacking, and that multilineage expanded PBSC do not reduce thrombocytopenia, we suggest that instead of multilineage expansion selective neutrophil expansion based on this relatively simple cytokine combination might be prioritized for development for clinical use as an adjunct to unmanipulated PBSC transplantation to reduce or abrogate post-transplant neutropenia.</p>
url http://www.translational-medicine.com/content/5/1/53
work_keys_str_mv AT turnermarcl optimalitexvivoitexpansionofneutrophilsfrompbsccd34supsupcellsbyacombinationofscfflt3landgcsfanditsinhibitionbyfurtheradditionoftpo
AT daviesjohn optimalitexvivoitexpansionofneutrophilsfrompbsccd34supsupcellsbyacombinationofscfflt3landgcsfanditsinhibitionbyfurtheradditionoftpo
AT roddiehuw optimalitexvivoitexpansionofneutrophilsfrompbsccd34supsupcellsbyacombinationofscfflt3landgcsfanditsinhibitionbyfurtheradditionoftpo
AT barclaygrobin optimalitexvivoitexpansionofneutrophilsfrompbsccd34supsupcellsbyacombinationofscfflt3landgcsfanditsinhibitionbyfurtheradditionoftpo
AT turaolga optimalitexvivoitexpansionofneutrophilsfrompbsccd34supsupcellsbyacombinationofscfflt3landgcsfanditsinhibitionbyfurtheradditionoftpo
_version_ 1725331855696199680